… Some studies also demonstrated that a booster dose (third dose) elicited … dose [14].
Here we report the immunogenicity and safety of a 3-dose regimen of an inactivated SARS-CoV-2 …

… However, to the best of our knowledge, ours is the only … safety set includes all participants
who received one dose of the vaccine (n=375). Dose 1 events are from days 0–7 and dose 2 …

… To obtain the best experience, we recommend you use a more up to date browser (or turn
off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we …

… safety outcomes 28 days and immunogenicity outcomes 14 days after 3 doses in a phase 1
trial and 2 doses in … June 16, 2020, and recommended that the preliminary analysis report be …

… To obtain the best experience, we recommend you use a … received two intramuscular doses
2 weeks apart and the safety and … correlates of protection against COVID-19 or SARS-CoV-2 …

… and safety of XAV-19, a … coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related
moderate pneumonia. The objective was to evaluate the optimal dose and safety …

… trial evaluating the safety and humoral immune responses following two doses of COVID-19 …
Administration of two consecutive doses, 3 weeks apart, of BNT162b2 was overall safe. The …

… Our findings indicate that, while the best performing candidate vaccine formulation among
… and dose needed to ensure optimal immune responses, including in those most at risk. …

… 1 dose of an inactivated SARS-CoV-2 … the safety and efficacy of Paxlovid in children.
Secondly, the blood concentration levels of Paxlovid were not tested, therefore the optimal dosage …

… dose of 200 mg given twice daily for 4 days is recommended for … well as its more tolerable
safety profile in comparison to chloroquine… drug for the treatment of SARS-CoV-2 infection [24]. …